Daniel A. Moon

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Journal: The Lancet. Oncology

Published: February 13, 2026

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.

Journal: The Lancet. Oncology

Published: February 06, 2026

Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative Analysis.

Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative Analysis.

Journal: Cancers

Published: February 04, 2026

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

Journal: The Lancet. Oncology

Published: December 20, 2025

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Journal: European urology oncology

Published: December 12, 2025

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial.

Journal: European urology oncology

Published: December 12, 2025

Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications.

Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications.

Journal: Cancers

Published: November 12, 2025

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Journal: Nature communications

Published: October 20, 2025

Robotic-assisted radical prostatectomy in patients 80+ years: a multi-centre experience.

Robotic-assisted radical prostatectomy in patients 80+ years: a multi-centre experience.

Journal: Journal of robotic surgery

Published: October 05, 2025

The Artificial Urinary Sphincter Clinical Outcomes Trial: Primary Results.

The Artificial Urinary Sphincter Clinical Outcomes Trial: Primary Results.

Journal: The Journal of urology

Published: October 03, 2025

Achondroplasia treatments in children aged 5 and older.

Achondroplasia treatments in children aged 5 and older.

Journal: Molecular and cellular pediatrics

Published: July 26, 2025

Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Impact of the R.E.N.A.L. complexity score on outcomes of stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Journal: BJU international

Published: June 28, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026